stockrowGyre Therapeutics, Inc. (GYRE) vs Phathom Pharmaceuticals, Inc. (PHAT)
- Gyre Therapeutics, Inc. GYRE 4.72 +17.71%
- Phathom Pharmaceuticals, Inc. PHAT 5.23 +2.95%
Gyre Therapeutics, Inc. and Phathom Pharmaceuticals, Inc. are both Biotechnology companies. Gyre Therapeutics, Inc. and Phathom Pharmaceuticals, Inc. are of similar size ($425.2M and $413.0M). Phathom Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 86.8% against 13.5%. Gyre Therapeutics, Inc. has the higher net margin (−21.5% vs −30.2%) and the lower return on invested capital (−8.51% vs 0.00%). Across the 16 metrics below, Phathom Pharmaceuticals, Inc. leads on 9 and Gyre Therapeutics, Inc. on 7.
Valuation
Profitability
| Metric | GYRE | PHAT | Biotechnology median |
|---|---|---|---|
| Gross margin | 91.71% | 80.68% | 68.51% |
| Operating margin | 0.00% | (9.26%) | 0.00% |
| Net margin | (21.46%) | (30.19%) | 0.00% |
| Free cash flow margin | (19.94%) | (7.65%) | 0.00% |
| Return on equity | (18.54%) | 21.55% | (51.96%) |
| Return on assets | (14.49%) | (28.36%) | (46.06%) |
| Return on invested capital | (8.51%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack